cyrilzakka/clinical-trials huggingface dataset:
Turkish Version of the Mini-BESTest: Transcultural Adaptation and Validation Study in Stroke Patients

"mini-BESTest (Turkish version)", "Berg Balance Test", "Timed Up and Go Test" and "Functional Reach Test" will be used for balance measurement in patients and the correlation of the mini-BEST with these tests will be checked.

The first part of the study is the Turkish translation of mini-BESTest. After the translation process, "mini-BESTest (Turkish version)", "Berg Balance Test", "Timed Up and Go Test" and "Functional Reach Test" will be used for balance measurement in patients and the correlation of the mini-BEST with these tests will be checked. All tests will be applied by 2 researchers on the same day, 2 times with 10 minutes intervals.

Eligibility Criteria:
Inclusion Criteria:

1. Chronic stroke patients
2. Patients who can execute commands
3. Patients who are ambulatory enough to complete most balance tasks
4. Patients participating in the study voluntarily

Exclusion Criteria:

1. Acute stroke patients
2. Patients who cannot execute commands
3. Non-ambulatory patients
4. Pediatric patients and pregnant patients
The Clinical Evaluation of Probiotics Product in Patients With Various Functional Bowel Disorders and Helicobacter Pylori Infection

People nowadays tend to have irregular diet and routine due to the stress at work. This condition may cause intestinal microflora imbalance, and in the long term may lead to constipation, diarrhea, gastroenteritis, gastric ulcer and other gastrointestinal diseases. Helicobacter pylori infection, which can trigger gastrointestinal inflammation and ulcer, is commonly treated by antibiotics. This treatment, however, can reduce the diversity of the intestinal microflora, causing diarrhea, flatulence and nausea. Clinical trials showed that probiotics and prebiotics supplementation could regulate gastrointestinal function, including alleviating constipation, ameliorating antibiotic-associated diarrhea and flatulence, enhancing the effect of H. pylori treatment, and restoring the balance of intestinal microflora. This Probiotics product is a supplement containing several types of probiotics and prebiotics which has been marketed for years. This project aims to observe the effectiveness of Probiotics product consumption by H. pylori-infected patients in relieving the gastrointestinal symptoms and restoring their intestinal microflora.


Eligibility Criteria:
Inclusion Criteria (PART I : For patients with bowel disorders):

* Constipation : Must include 2 or more of the following:

  * straining during at least 25% of defecations
  * lumpy or hard stools in at least 25% of defecations
  * sensation of incomplete evacuation for at least 25% of defecations
  * sensation of anorectal obstruction/blockage for at least 25% of defecations
  * manual maneuvers to facilitate at least 25% of defecations
  * fewer than 3 defecations per week
* Diarrhea :

  * the passage of 3 or more loose or liquid stools per day and lasting more than 1 week, or more frequently than is normal for the individual.

Inclusion Criteria (PART II : For patients with Helicobacter pylori infection):

* Campylobacter-like organism test (CLO test) positive

Exclusion Criteria (PART I \& II)

* prior upper digestive tract surgery
* a history of cancer
* lactose intolerance
* allergy to penicillin
* prior antibiotics therapy in the last month
* prior probiotics supplement more than once a week in the last three weeks
Amino Acid Usage Patterns in Daily Practice

The present study aims to evaluate the patient profile including medical conditions who use a nutritional supplement along with a balanced and varied diet in Turkey.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years old.
* Consuming amino acid containing oral nutritional supplement before enrolment for malnutrition for hard-to-heal wounds or malnutrition due to primary disease.
* Followed by internal medicine or surgery departments.

Exclusion Criteria:

* History of allergy or hypersensitive reaction to any ingredient in the amino acid containing oral nutritional supplement.
* History of any food allergy or intolerance
Anterior Segment Spectral-domain Optical Coherence Tomography in Patients With Closed Globe Injury

This study use anterior segment spectral-domain optical coherence tomography (SD-OCT) to exam patients with closed globe injury, and compared with slit lamp examination. The results showed that OCT can identify features of closed globe injury that were otherwise not visible on slit lamp biomicroscopy.

The anterior segment architecture changes of closed globe injury patients include corneal damage, hyphema, angle recession and lens dislocation, which can be showed with OCT. OCT was superior to slit lamp biomicroscopy examination in detecting anterior segment architecture changes, especially in the presence of media opacities.

Eligibility Criteria:
Inclusion Criteria:

* patients with closed globe injury were recruited; had hyphema at least 1/3 of anterior chamber volume

Exclusion Criteria:

* can not cooperate with examination
Neuromusuclar Adaptations in the Rheumatoid Arthritis Disease

Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes joint inflammation and progressive joint destruction. Rheumatoid cachexia is one of the structural manifestations of RA, and consists of a reduction in muscle mass, due to an increased muscle protein catabolism induced by inflammatory cytokines. This muscle mass loss generates an impairment in physical function and functional capacity in RA patients. The aim of study was to verify neuromuscular and functional responses in middle-aged women with RA compared to paired healthy women.


Eligibility Criteria:
Inclusion Criteria:

* RA patients with a class I and II RA diagnosis according to the American Rheumatism Association's 1987 revised criteria, were recruited from a university hospital's rheumatology clinic.

Exclusion Criteria:

* presence of any cardiovascular, neuromuscular and metabolic diseases or severe limitations in mobility
Parental Feelings About Their Child Needing a Central Line

The goal of this research project is to determine if different communication techniques during the consent process impact parental anxiety and comfort providing consent.

The parents of children in the pediatric intensive care units (PICUs) at Columbia University may be asked if they are interested in participating in this study if their child needs a central venous line (CVL) or peripherally inserted central catheter (PICC) placed.

If the parents are interested in participating, they will be randomly assigned to a communication technique group while they are discussing the procedure and giving consent with a medical team member. After they provide consent, they will be asked to complete surveys about their thoughts and feelings. The study should take about 15 minutes.

After data is collected, the researchers will compare survey answers between the two communication styles used with parents.

Eligibility Criteria:
Inclusion Criteria:

* Parent or guardian of a child admitted to the pediatric intensive care units (PICUs) at Columbia University
* The child needs a central venous line (CVL) or peripherally inserted central catheter (PICC) placed in the PICU
* The parent or guardian speaks English or Spanish

Exclusion Criteria:

* Parents or guardians who speak languages other than English or Spanish
* Parents or guardians of children who need a CVL or PICC placed during an emergency without consent
* Parents or guardians who are unable to be physically present and provide consent over the phone
Open-glottis Pushing Technique Versus the Valsalva Pushing Technique in the Second Stage of Labor

Pushing has been discussed for decades, primarily in terms of facilitating care in the second stage of labor and maternal/fetal outcomes.

Valsalva-type pushing is the pushing performed by a pregnant woman by holding her breath. Various physiological findings argue against the Valsalva maneuver may adversely affect the acid-base balance and cerebral oxygenation of the fetus. It has been shown that a long apnea period (long closed glottis) associated with the Valsalva maneuver during the expulsive stage of labor increases lactate concentration in the mother and the fetus and adversely affects the fetal acid-base balance.

Spontaneous pushing is the pushing movements that occur naturally in the second stage of birth. Spontaneous pushing is part of the natural birth process and encourages women to trust the natural functioning of their bodies. When pushing with an open glottis, fetal placental circulation is preserved since the pressure on the chest does not increase and there are fewer hemodynamic effects.

The World Health Organization (WHO) recommends that women in the second stage of labor should be encouraged and supported to follow their pushing urges. The WHO states that healthcare professionals involved in obstetric care should avoid the Valsalva maneuver due to the lack of evidence that this technique has any benefit in the second stage of labor. The WHO supports spontaneous pushing in its recommendations for a positive birth experience. Safe termination of labor for both the mother and fetus is one of the primary duties of all healthcare professionals. There are few studies examining the maternal and fetal effects of the pushing types used during labor, especially their effects on the acid-base balance in the fetus. To contribute to the quality of evidence on the subject, the effects of Valsalva-type and spontaneous pushing techniques in the second stage of labor on fetal acid-base level and maternal outcomes were examined.

Hypotheses of the Research H1: Spontaneous pushing reduces the mother's pain level. H2: Spontaneous pushing increases the mother's birth satisfaction. H3: Spontaneous pushing positively affects the acid-base balance of the fetus. H4: Valsalva-type pushing increases the mother's pain level. H5: Valsalva-type pushing reduces the mother's birth satisfaction. H6: Valsalva-type pushing negatively affects the acid-base balance of the fetus.


Eligibility Criteria:
Inclusion Criteria:

Being at least a primary school graduate, being between the 38th and 42nd weeks of gestation, having a single fetus in a vertex position, giving vaginal birth, not developing any complications during labor, and volunteering to participate in the study.

Exclusion Criteria:

High-risk pregnancy, developing complications during labor, and having a diagnosed psychiatric disease.
Clinician Decision Making Regarding Surveillance for Low-risk Intraductal Papillary Mucinous Neoplasms of The Pancreas

The main objective of this study is to determine how physicians make decisions regarding surveillance of Intraductal Papillary Mucinous Neoplasm's (IPMN) of the pancreas.

The study will employ a survey design that poses physicians with a series of three clinical case vignettes. Each vignette describes an IPMN of varying severity, and the physician will be asked determine whether they would continue or discontinue clinical surveillance in each case.

This will be a double-blinded randomized survey study, featuring two arms. Providers will be randomized to either be provided with, or not provided with a risk stratification tool (DART-1) when presented with their clinical case vignettes.

Eligibility Criteria:
Inclusion Criteria:

* Membership in either the PACYFIC or PRECEDE consortiums
* Physician with expertise in the management of IPMN
* Able and willing to complete survey

Exclusion Criteria:

* Not a member of either the PACYFIC or PRECEDE consortiums
* Not a physician with expertise in the management of IPMN
Impact of SH T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D01155E) on Hemostatic Parameters

The aim of this study is to evaluate the impact of SH T00658ID (EV/DNG tablet) on hemostatic parameters in comparison to a reference oral contraceptive (OC) (SH D01155E) in a crossover design.

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Eligibility Criteria:
Inclusion Criteria:

* Healthy female volunteers

Exclusion Criteria:

* Pregnancy or lactation
* Any condition that might interfere with the outcome as all contraindications for OC use.
Prospective Assessment of CONECCT's Classification for Colorectal Lesions.

Colorectal neoplastic lesion endoscopic characterization is a key element for histological predictive diagnostic value in conducting best appropriate resection choice. Six classifications are necessary for fully correct characterization of different colorectal lesions. Nonetheless, it can be tricky to use so many diagnostic tools with so many subcategories in the 6 existing classifications. That's why we decided to integrate all 6 existing classification validated factors in one single chart (CONECCT chart) allowing to both predict histological diagnostic value and to propose the best appropriate resection strategy. A previous prospective and multicentre study with all French medical residents in gastroenterology was conducted in order to prove pedagogic interest of this diagnostic tool. Each student was asked to review 20 files with lesion pictures before and after lecture about CONECCT chart. This allowed us to prove that this diagnostic tool could significantly improve both histological predictive diagnostic value and therapeutic choice by French medical residents and gastroenterologists. Our hypothesis is that CONECCT's classification can improve predictive diagnostic value of colorectal lesions in over 80% of cases. Now that pedagogic interest of this diagnostic tool has been proven, we would like to carry out a larger prospective assessment in term of performance (value) of this instrument in order to both facilitate endoscopic characterization and allow a most appropriate diagnostic and therapeutic management of each colorectal lesion category.


Eligibility Criteria:
* Inclusion Criteria :

  * both gender patients even or older than 18 years old
  * patient in need of proven diagnostic or therapeutic colonoscopy for colorectal lesion resection
  * patient with French Health Insurance coverage
  * obtaining of oral non opposition to research after loyal, clear and complete delivery of information
* Exclusion Criteria :

  * previous attempt of lesion resection by mucosectomy
  * patient with a metastatic lesion diagnosed prior to colonoscopy
  * patient with no colorectal lesion
  * adenomatous or sessile serrated polyposis syndrome
  * patient with bowel chronic inflammatory disease
Swallowing Evaluation by HRIM in Patients With Cervical Spondylosis

patients with cervical spondylolysis may have swallowing or eating difficulty. In this study, we will use high resolution impedance manometry to evaluate these patients' detailed swallowing mechanisms.

This study will aim to evaluate swallowing function in patients with cervical spondylolysis by using high resolution impedance manometry (HRIM) along with oral frailty and dysphagia questionnaires. Researchers will plan to enroll 50 patients to investigate this issue. The inclusion criteria will be as following:1) age higher or equal to 20 years old; 2) patients with cervical spondylolysis or associated symptoms. The exclusion criteria will be as following: major organ dysfunction, including chronic kidney disease, bleeding tendency. The primary outcome will be the upper esophageal sphincter relaxing pressure. The researchers will hope to find the swallowing dysfunction mechanisms in these patients.

Eligibility Criteria:
Inclusion Criteria:

* patients with cervical spondylosis associated symptoms or expected to undergo cervical spine surgery
* patients with associated swallowing difficulty symptoms

Exclusion Criteria:

* major organ dysfunction, such as renal insufficiency or bleeding tendency
Impact of qSOFA Calculation on the Timing of Antimicrobial Therapy in the Emergency Department

The delayed administration of an adequate antimicrobial therapy is a strong predictor of impaired outcome in patients with bacterial sepsis. Therefore, the current Surviving Sepsis Campaign guidelines (2016) recommend that administration of intravenous antimicrobials be initiated within one hour following the recognition of sepsis or septic shock.

The quick Sepsis-related Organ Failure Assessment (qSOFA) score is a new bedside tool which has been recently proposed by the Third International Sepsis Consensus Definitions Task Force (Sepsis-3) to identify patients with suspected infection who are at greater risk for a poor outcome outside the Intensive Care Unit (ICU). It uses three criteria, assigning one point for low systolic blood pressure (SBP ≤100 mmHg), high respiratory rate (≥22 breaths per min) and altered mentation (Glasgow coma scale \<15). The score ranges from 0 to 3 points. A qSOFA value ≥2 points is associated with a greater risk of death or prolonged ICU stay, these outcomes being more common in infected patients who may be septic than in those with uncomplicated infection. The definite goal of qSOFA is to hasten the management and thus improve the outcome of patients at risk of sepsis or septic shock.

Many patients admitted to the hospital for bacterial sepsis or septic shock are initially managed in the Emergency Department (ED). This study aims at investigating whether the routine calculation of qSOFA at patient triage may hasten the initiation of antimicrobial therapy in patients admitted to the ED with suspected or proven bacterial infection, especially in those with subsequent criteria for sepsis or septic shock (Sepsis-3 definition).


Eligibility Criteria:
Inclusion Criteria:

• Suspected or proven bacterial infection at emergency department triage

Exclusion Criteria:

* Imminent death
* Pregnancy
* Breast-feeding
* For patients managed by a medicalized pre-hospital emergency team before ED admission : administration of a first dose of antimicrobial agent before ED admission
* Lack of coverage by the public health insurance system
* Patient's refusal for study enrollment
* Lack of confirmed bacterial infection (i.e., documented either clinically, microbiologically or by imaging procedures) in patients with a suspected bacterial infection at emergency departement triage
Ultrasound Guided Percutaneous Microwave Ablation for Breast Lesions

The investigators will perform this study to prospectively analyse the clinical outcome after percutaneous microwave ablation(MWA) of benign and malignant breast lesion under ultrasound (US) guidance.

A total of more than 500 patients diagnosed with benign breast lesions and 50 patients with malignant breast lesions in seven centers of China will be recruited in this study and underwent US-guided percutaneous MWA treatment. Information for each patient includes demographics; longest diameters of tumors; tumor numbers; tumor pathological type; location of tumor according to whether adjacent to skin, pectoralis, areola and papilla. Ablation variables including session, puncture, time, and power; complete ablation, complications; reduction in volume, palpability, pain and cosmetic satisfying outcomes,recurrence,survival will be measured and analyzed.

Eligibility Criteria:
Inclusion Criteria:

* breast lesion proved by using core-needle biopsy;
* for benign lesions,lesion 1.0 cm or larger in greatest diameter and continually increasing during a half year follow-up; for malignant ones, lesion size 2cm or smaller;
* distance of at least 1.0cm to papilla with the patients supine;
* the symptoms of local pain, discomfortable or compression considered probably relating to the lesion of breast;
* the patient with evidently psychological pressure due to the occurrence of the lesion;
* patients unwilling or refused to receive other treatment and presence of an appropriate route for percutaneous puncture under US guidance.

Exclusion Criteria:

* patients who were pregnant or breast-feeding;
* patients with evidence of coagulopathy or acute or severe pulmonary insufficiency or heart dysfunction;
* patients during menstrual period;
* patients who wanted to undergo other therapies including surgical excision and vacuum-assisted biopsy.
A Study of JZP150 in Adults With Posttraumatic Stress Disorder

This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP150 in the treatment of adult participants with post-traumatic stress disorder (PTSD).

JZP150 is an oral, highly selective inhibitor of fatty acid amide hydrolase (FAAH). In this phase 2 study, participants with PTSD will receive either placebo or 1 of 2 doses of JZP150. The primary objective of the study will assess the change in PTSD symptoms from baseline to Week 12 using the Clinician Administered PTSD Scale (CAPS-5).

Eligibility Criteria:
Inclusion Criteria:

* Participants aged 18 to 70 years
* Participants must be outpatients with a primary diagnosis of Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) defined PTSD confirmed by the clinical interview
* PTSD is primary diagnosis

Exclusion Criteria:

* Acute or unstable medical condition, behavioral or psychiatric disorder (other than PTSD)
* Suicidal behavior in the past 2 years or active suicidal ideation in the past 6 months
* Ongoing traumatic event or exposure to a traumatic event \<3 months prior to Screening
* Index event \> 12 years
* Index event is combat trauma
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.

This is a Randomized, open-label, single oral dosing, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of CKD-383 and the co-administration of CKD-501, D745, and D150 for healthy subjects in fed state

Participants were randomly assigned in a 1:1 ratio. The patients are prescribed oral administration of the appropriate IP(2 or 4 tablets in single dose: actual medication)

Eligibility Criteria:
Inclusion Criteria:

* Healthy adults aged 19 to 65 years
* Based on screening, no congenital or chronic disease, who have no athological symptoms or findings(If necessary, EEG, ECG, chest and gastroscopy or gastrointestinal radiation, Examination)
* within 5 years prior to the start of the trial(Period 1 administration) of any clinically significant mental medical history
* Other inclusion criteria, as defined in the protocol

Exclusion Criteria:

* who has taken drug metabolism enzyme induction and inhibitory drugs, such as barbitale drugs, within 30 days prior to the start of the trial (Period 1 administration)
* Other exclusive criteria, as defined in the protocol